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Monday, February 4, 2013 299a(i.e., A-N interdomain distance). FRET results were compared to distance
predictions from x-ray crystallography. We propose a structural mechanism
for ligand activation of SERCA. Acknowledgments: Spectroscopy was per-
formed in the Biophysical Spectroscopy Center at the University of Minnesota,
with assistance from Fluorescence Innovations, Inc. (Gregory Gillispie, Presi-
dent). This work was funded by NIH grants to DDT (R01 GM27906, P30
AR0507220, T32 AR007612).
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We used a prototype time-resolved fluorescence lifetime microplate reader to
carry out a high-throughput screen designed to identify compounds that inter-
act with the sarcoplasmic reticulum calcium ATPase (SERCA). SERCA is
essential for the Ca homeostasis in many cell types. Insufficient SERCA activ-
ity leads to cardiovascular disease, muscular dystrophy, skin disease, and
diabetes. Our goal is to discover activators of SERCA that can be developed
into drugs to treat diseases in which Ca transport is deficient. The fluorescence
lifetime plate reader was made possible by our recent development of fast
time-resolved fluorescence by direct waveform recording, which achieves
105 higher throughput than the conventional single-photon counting technol-
ogy. using this plate reader, we detected fluorescence resonance energy trans-
fer (FRET) between IAEDANS-labeled SERCA and nucleotide analog
TNPADP in native sarcoplasmic reticulum membranes. This assay was de-
signed to detect compounds that interact with SERCA and modify either the
enzyme’s structure or the binding affinity of TNP-ADP. Initial hit compounds
were further analyzed in functional assays. Upon screening a small (1300 com-
pound) library, we determined that the time-resolved microplate reader has at
least 10x higher precision than a conventional intensity-based microplate
reader, raising the quality index (z’) of our assay from marginal, in the inten-
sity reader, to excellent. A 384-well plate is read with high precision in 2 min,
which allows screening of thousands of compounds/day. An important advan-
tage of the time-resolved fluorescence measurement is that it provides detailed
structural information, thus enabling discovery of multiple classes of com-
pounds during the primary screen.
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We are using in-cell FRET methods (Photobleaching, FLIM, time-resolved
FRET in a plate reader) to study the relationships among structure, dynamics,
and function of the sarcoplasmic reticulum Ca-ATPase (SERCA) and its
cardiac regulator phospholamban (PLB), with the goal of designing activators
of SERCA for treatment of heart failure (HF) and muscular dystrophy (MD).
Ca2þ drives muscle contraction, and relaxation is accomplished by the seques-
tration of Ca2þ by the sarcoplasmic reticulum Ca-ATPase (SERCA), which is
inhibited by phospholamban at submicromolar [Ca2þ] in cardiac muscle.
SERCA activity is frequently reduced in HF, and many current therapeutic
strategies aim to increase cardiac Ca2þ cycling activity. We are designing
LOF-PLB mutants (PLBM) that can compete with WT-PLB (PLBW) and
thus relieve SERCA inhibition. Our ideal mutant is partial loss-of-function,
binds tightly to SERCA2a, and remains phosphorylatable via b-adrenergic
pathways. The effects of PLBM on Ca-ATPase activity and FRET are measured
to determine the mutant’s ability to compete with PLBW, both physically and
functionally. Optimal LOF mutants are being tested in a rat model of heart
failure.
In addition to this SERCA-PLB FRET competition assay, we are using
SERCA2a labelled with two different fluorescent probes (GFP and RFP) to
screen for small molecule activators of SERCA in living cells. Time-
resolved FRETmeasurements of RFP-GFP-SERCA2a in 96- or 384-well plates
have shown the extraordinary precision and sensitivity necessary to probe
SERCA’s structure-function relationship. New drug screening efforts are active
and small molecules from previous screens are being developed as promising
drugs for HF therapy (collaboration with Celladon, Inc.). Many of these drugs
are direct SERCA activators and are being investigated for their ability to
rescue the muscular dystrophy phenotype in dystrophic mice.1531-Pos Board B423
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We have used site-directed spin labeling and electron paramagnetic resonance
(EPR) spectroscopy to investigate the effects of Ser16 phosphorylation on
phospholamban’s interaction with the sarcoplasmic reticulum Ca-ATPase
(SERCA). Muscle contraction is signaled by the release of Ca from the sarco-
plasmic reticulum (SR), while SERCA mediates muscle relaxation by actively
pumping Ca back into the SR lumen. Cardiac SERCA is regulated by phospho-
lamban (PLB), a single-pass transmembrane protein that inhibits the Ca pump
unless phosphorylated at Ser16.
We have shown that Ser16 phosphorylation does not dissociate PLB from
SERCA to relieve inhibition, but instead induces a structural change in
PLB’s transmembrane (TM) helix that restores SERCA Ca sensitivity. To
characterize this change, we have attached spin labels along the TM helix
and performed EPR accessibility measurements to determine the effects of
Ser16 phosphorylation on TM helix topology within the regulatory complex.
Our results show that upon phosphorylation, the TM helix undergoes a vertical
shift that could break inhibitory interactions between SERCA and PLB. Com-
plementary ongoing studies employ these spin-labeled PLB constructs to deter-
mine changes in (a) the orientation of PLB and (b) distances to probes on
SERCA, with the goal of obtaining a detailed structural model for the regula-
tory transitions within the SERCA-PLB complex.
1532-Pos Board B424
Orientation of Phospholamban in Lipid Bicelles Detected by Electron
Paramagnetic Resonance
JesseE.McCaffrey, ZacharyM. James,ChristineB.Karim,DavidD.Thomas.
University of Minnesota: Twin Cities, Minneapolis, MN, USA.
We have used electron paramagnetic resonance (EPR) to probe the structural
dynamics of the integral membrane protein phospholamban (PLB), as a function
of phosphorylation and addition of its regulatory target, the sarcoplasmic retic-
ulum calcium ATPase (SERCA). We found previously that PLB remains bound
to SERCA after phosphorylation, suggesting that a structural transition within
the SERCA-PLB complex is responsible for relief of inhibition. Our current
goal is to elucidate this mechanism through orientation and accessibility
EPR, in order to support rational design of therapies to improve calcium
transport in muscle cells. We used the monomeric mutant AFA-PLB,
with the rigid electron spin label TOAC in-
corporated within the transmembrane
domain, and reconstituted the protein in
lipid bicelles and vesicles. EPR showed
that the accessibilities of PLB spin labels
to paramagnetic relaxation agents changed
upon phosphorylation, indicating vertical
(parallel to the membrane normal) move-
ment of PLB. EPR on aligned bicelles
showed that PLB changes its tilt relative
to the membrane upon phosphorylation.
Results will also be reported on structural
changes in the presence of SERCA. This
work was funded by grants from NIH
(R01 GM27906 and T32 AR007612).1533-Pos Board B425
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We have used time-resolved fluorescence resonance energy transfer (TR-
FRET) to study the structural basis of regulation of sarcoplasmic reticulum
Ca2þ ATPase (SERCA) by a single-pass transmembrane protein, phospholam-
ban (PLB). The most prominent feature of heart failure is calcium mishandling,
which is largely due to impaired activity of sarcoplasmic reticulum calcium
ATPase (SERCA), which actively transports Ca2þ from cytosol into the SR
to relax the muscle. Unphosphorylated phospholamban inhibits SERCA by
decreasing its apparent Ca2þ affinity. This inhibition can be relieved by either
micromolar Ca2þ or by phosphorylation of PLB. The structural basis for relief
of inhibition remains controversial. Cross-linking studies support the canonical
dissociation model. However, recent EPR, NMR and FRET studies support
the subunit model, in which subtle structural rearrangements are required to
